Related Experiment Video
Updated: Sep 26, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
Carbon monoxide and β-cell function: Implications for type 2 diabetes mellitus.
Zahra Bahadoran1, Parvin Mirmiran2, Khosrow Kashfi3
1Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Carbon monoxide (CO) aids carbohydrate metabolism by stimulating insulin secretion and protecting pancreatic cells. It shows therapeutic potential for type 2 diabetes mellitus (T2DM) and pre-diabetes.
Area of Science:
- Biochemistry
- Endocrinology
- Metabolic Research
Background:
- Carbon monoxide (CO) is a gasotransmitter involved in cellular signaling.
- Heme oxygenases (HO-1 and HO-2) produce CO, influencing carbohydrate metabolism.
- CO plays a role in insulin secretion and pancreatic beta-cell function.
Purpose of the Study:
- To investigate the role of carbon monoxide in carbohydrate metabolism and insulin secretion.
- To explore the therapeutic potential of CO in pre-diabetes and type 2 diabetes mellitus (T2DM).
- To understand the interaction of CO with other gasotransmitters like nitric oxide (NO) and hydrogen sulfide (H2S).
Main Methods:
- Review of experimental evidence on CO's effects on insulin secretion and beta-cell function.
- Analysis of CO's protective mechanisms against apoptosis and its role in beta-cell regeneration.
- Examination of CO's cross-talk with NO and H2S in regulating metabolic processes.
Main Results:
- Both HO-1 and HO-2 derived CO stimulate insulin secretion.
- CO protects pancreatic beta-cells from apoptosis induced by cytokines and hypoxia.
- CO promotes beta-cell regeneration and interacts with NO and H2S for metabolic regulation.
Conclusions:
- CO demonstrates significant therapeutic potential for T2DM and pre-diabetes management.
- CO-releasing molecules or natural HO inducers are potential candidates for CO-based T2DM therapeutics.
- Further research is required to evaluate the safety and efficacy of CO-based therapies for T2DM.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Symptoms, Diagnosis, and Complications
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...

